While another inflammatory biologic is making strides in the hidradenitis suppurativa treatment domain, Cosentyx by Novartis currently holds a significant lead. This advantage is crucial for Swiss Pharma, especially as dermatology experts anticipate strong competition from UCB’s bimekizumab, recently approved as Bimzelx for plaque psoriasis treatment and seeking approval for hidradenitis suppurativa treatment as well. On October 31, the FDA approved Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa in adults, marking the first approval of a new biologic for this skin condition in nearly a decade.
Hidradenitis Suppurativa, recognized as Acn...
